Log In
BCIQ
Print this Print this
 

CBS9106, SL-801

  Manage Alerts
Collapse Summary General Information
Company CanBas Co. Ltd.
DescriptionReversible inhibitor of exportin 1 (XPO1; CRM1)
Molecular Target Exportin 1 (XPO1) (CRM1)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
PartnerStemline Therapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/07/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today